AMENDMENT NO. 3 to the LICENSE AGREEMENT dated as of March 31, 2004 (as amended prior to the date hereof)License Agreement • August 8th, 2011 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 3 (the “AMENDMENT NO. 3”), dated and effective as of the 8th day of June, 2011 (the “AMENDMENT NO. 3 EFFECTIVE DATE”) to that certain LICENSE AGREEMENT dated as of March 31, 2004, as amended by that certain AMENDMENT NO. 1 dated as of December 22, 2004 and that certain AMENDMENT NO. 2 dated as of July 27, 2006 (collectively referred to herein as the “LICENSE AGREEMENT”), by and between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”), and OREXIGEN THERAPEUTICS, INC., a Delaware corporation (“OREXIGEN”). Unless otherwise defined herein, capitalized terms used but not defined herein shall have the meaning set forth in the LICENSE AGREEMENT, and the LICENSE AGREEMENT shall be amended to incorporate any additional definitions provided for in this AMENDMENT NO. 3.
